The DOI matches its Crossref record; 286 of the 286 references it cites were found in a registry or an index.
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Open accessAbstract
The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in regulation of cell survival, metabolism, growth and protein synthesis in response to upstream signals in both normal physiological and pathological conditions, especially in cancer. Aberrant mTOR signaling resulting from genetic alterations from different levels of the signal cascade is commonly observed in various types of cancers. Upon hyperactivation, mTOR signaling promotes cell proliferation and metabolism that contribute to tumor initiation and progression. In addition, mTOR also negatively regulates autophagy via different ways. We discuss mTOR signaling and its key upstream and downstream factors, the specific genetic changes in the mTOR pathway and the inhibitors of mTOR applied as therapeutic strategies in eight solid tumors. Although monotherapy and combination therapy with mTOR inhibitors have been extensively applied in preclinical and clinical trials in various cancer types, innovative therapies with better efficacy and less drug resistance are still in great need, and new biomarkers and deep sequencing technologies will facilitate these mTOR targeting drugs benefit the cancer patients in personalized therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–286 of 286
Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt
Zhang, J., Xu, K. L., Liu, P., Geng, Y., Wang, B., Gan, W., Guo, J., Wu, F., Chin, Y. R., Berrios, C. J., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.04.023 · Cited by 108
Self-citationFaes, S., Demartines, N., & Dormond, O. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1726078 · Cited by 107
Morris, L. G. T., Taylor, B. S., Bivona, T. G., Gong, Y., Eng, S., Brennan, C., Kaufman, A., Kastenhuber, E. R., Banuchi, V., Singh, B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111963108 · Cited by 106
The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress
Bahrami, A., Khazaei, M., Shahidsales, S., Hassanian, S. M., Hasanzadeh, M., Maftouh, M., Ferns, G. A., & Avan, A. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26136 · Cited by 106
Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis
Nam, S. Y., Lee, H. S., Jung, G., Choi, J., Cho, S. J., Kim, M. K., Kim, W. H., & Lee, B. L. (2003) · Apmis · doi:10.1111/j.1600-0463.2003.apm1111205.x · Cited by 104
PI3K/AKT pathway activation in bladder carcinogenesis
Caldéraro, J., Rebouissou, S., de Koning, L., Masmoudi, A., Hérault, A., Dubois, T., Maillé, P., Soyeux, P., Sibony, M., TAILLE, A. D. L., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28518 · Cited by 102
Targeting the mTOR Signaling Pathway in Neuroendocrine Tumors
Chan, J. A., & Kulke, M. H. (2014) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0294-4 · Cited by 99
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
Price, K. A. R., Azzoli, C. G., Krug, L. M., Pietanza, M. C., Rizvi, N. A., Pao, W. J., Kris, M. G., Riely, G. J., Heelan, R. T., Arcila, M. E., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ec1531 · Cited by 97
Houédé, N., & Pourquier, P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.06.004 · Cited by 97
Bauman, J. E., Arias‐Pulido, H., Lee, S. J., Fekrazad, M. H., Ozawa, H., Fertig, E. J., Howard, J. D., Bishop, J. A., Wang, H., Olson, G. T., et al. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2012.12.016 · Cited by 93
Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2 -Amplified Breast Cancers
Joly, M. M., Hicks, D. J., Jones, B. A., Sanchez, V. M., Estrada, M. V., Young, C. D., Williams, M. M., Rexer, B. N., Sarbassov, D. D., Muller, W. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3393 · Cited by 92
Targeting PI 3‐kinase ( PI 3 K ), AKT and m TOR axis in lymphoma
Blachly, J. S., & Baiocchi, R. A. (2014) · British Journal of Haematology · doi:10.1111/bjh.13065 · Cited by 91
Li, X., Wang, Y. C., Li, W. S., & Du, Y. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-152 · Cited by 91
Self-citationMassarelli, E., Lin, H. Y., Ginsberg, L. E., Tran, H. T., Lee, J. J., Canales, J. R., Williams, M. D., Blumenschein, G. R., Lu, C. S., Heymach, J. V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv194 · Cited by 89
Zhang, Y., & Zheng, X.-F. (2012) · Cell Cycle · doi:10.4161/cc.11.3.19096 · Cited by 88
Mazumdar, T., Byers, L. A., Ng, P. K. S., Mills, G. B., Peng, S., Diao, L., Fan, Y.-H., Stemke‐Hale, K., Heymach, J. V., Myers, J. N., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1090 · Cited by 88
Bendell, J. C., Kelley, R. K., Shih, K. C., Grabowsky, J. A., Bergsland, E. K., Jones, S. F., Martin, T., Infante, J. R., Mischel, P. S., Matsutani, T., et al. (2015) · Cancer · doi:10.1002/cncr.29422 · Cited by 87
HER2 Expression and PI3K-Akt Pathway Alterations in Gastric Cancer
Sukawa, Y., Yamamoto, H., Nosho, K., Ito, M., Igarashi, H., Naito, T., Mitsuhashi, K., Matsunaga, Y., Takahashi, T., Mikami, M., et al. (2014) · Digestion · doi:10.1159/000356201 · Cited by 85
mTOR co-targeting strategies for head and neck cancer therapy
Wang, Z., Valera, J. L. C., Zhao, X., Chen, Q., & Gutkind, J. S. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9688-7 · Cited by 85
Seager, C. M., Puzio‐Kuter, A. M., Patel, T., Jain, S., Cordon‐Cardo, C., Kiernan, J. M., & Abate-Shen, C. T. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0169 · Cited by 84
Phase II trial of RAD001 and bicalutamide for castration‐resistant prostate cancer
Nakabayashi, M., Werner, L., Courtney, K. D., Buckle, G. C., Oh, W. K., Bubley, G. J., Hayes, J. H., Weckstein, D. J., Elfiky, A. A., Sims, D. M., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11456.x · Cited by 82
Dreher, T., Zentgraf, H., Abel, U. R., Kappeler, A., Michel, M., Bleyl, U., & Grobholz, R. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1004-6 · Cited by 82
Gonzalez-Angulo, A. M., Meric‐Bernstam, F., Chawla, S. P., Falchook, G. S., Hong, D. S., Akçakanat, A., Chen, H., Naing, A., Fu, S., Wheler, J. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3110 · Cited by 82
mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review)
Hu, K., Dai, H.-B., & Qiu, Z.-L. (2016) · Oncology Reports · doi:10.3892/or.2016.4922 · Cited by 82
Armstrong, A. J., Netto, G. J., Rudek, M. A., Halabi, S., Wood, D. P., Creel, P. A., Mundy, K., Davis, S. L., Wang, T., Albadine, R., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0124 · Cited by 81
Rad, E., Murray, J. T., & Tee, A. R. (2018) · Cancers · doi:10.3390/cancers10010005 · Cited by 80
Britten, C. D., Adjei, A. A., Millham, R., Houk, B. E., Borzillo, G. V., Pierce, K. J., Wainberg, Z. A., & LoRusso, P. M. (2014) · Investigational New Drugs · doi:10.1007/s10637-013-0062-5 · Cited by 79
Ekshyyan, O. Y., Rong, Y., Rong, X., Pattani, K. M., Abreo, F. W., Caldito, G. C., Chang, J. K. S., Ampil, F. L., Glass, J., & Nathan, C. O. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1184 · Cited by 78
Ng, K., Tabernero, J. M., Hwang, J. J., Bajetta, E., Sharma, S., Prete, S. A. D., Arrowsmith, E. R., Ryan, D. P., Šedová, M., Jin, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0027 · Cited by 78
Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis
Nardella, C., Carracedo, A., Alimonti, A., Hobbs, R. M., Clohessy, J. G., Chen, Z., Egia, A., Fornari, A., Fiorentino, M., Loda, M. F., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000189 · Cited by 77
Metformin-induced ablation of microRNA 21-5p releases Sestrin-1 and CAB39L antitumoral activities
Pulito, C., Mori, F., Sacconi, A., Goeman, F., Ferraiuolo, M. A., Pasanisi, P., Campagnoli, C., Berrino, F., Fanciulli, M., Ford, R. J., et al. (2017) · Cell Discovery · doi:10.1038/celldisc.2017.22 · Cited by 77
Activating mutations of TOR (target of rapamycin)
Hardt, M. E., Chantaravisoot, N., & Tamanoi, F. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01482.x · Cited by 76
mTOR in breast cancer: Differential expression in triple-negative and non-triple-negative tumors
Walsh, S., Flanagan, L., Quinn, C., Evoy, D., McDermott, E. W. M., Pierce, A., & Duffy, M. J. (2011) · The Breast · doi:10.1016/j.breast.2011.09.008 · Cited by 74
Ueng, S., Chen, S., Chang, Y., Hsueh, S., Lin, Y., Chien, H., Lo, Y.-F., Shen, S., & Hsueh, C. (2012) · Europe PMC (PubMed Central) · Cited by 70
Cejka, D., Preusser, M., Wöehrer, A., Sieghart, W., Strommer, S., Werzowa, J. M., Fuereder, T., & Wacheck, V. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.9.6416 · Cited by 70
mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Statz, C. M., Patterson, S. E., & Mockus, S. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0453-6 · Cited by 70
Klinghammer, K. F., Raguse, J. D., Plath, T., Albers, A. E., Joehrens, K., Zakarneh, A., Brzezicha, B., Wulf‐Goldenberg, A., Keilholz, U., Hoffmann, J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29344 · Cited by 65
Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
Chiong, E., Lee, I.-L., Dadbin, A., Sabichi, A. L., Harris, L. D., Urbauer, D. L., McConkey, D. J., Dickstein, R. J., Cheng, T., & Grossman, H. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3202 · Cited by 65
Besse, B., Leighl, N. B., Bennouna, J., Papadimitrakopoulou, V. A., Blais, N., Traynor, A. M., Soria, J., Gogov, S., Miller, N., Jehl, V., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt536 · Cited by 65
Clinical development of mTor inhibitors for renal cancer
Ghidini, M., Petrelli, F., Ghidini, A., Tomasello, G., Hahne, J. C., Passalacqua, R., & Barni, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1384813 · Cited by 64
Fury, M. G., Lee, N. Y., Sherman, E. J., Ho, A. L., Rao, S. D., Heguy, A., Shen, R., Korte, S. H., Lisa, D., Ganly, I., et al. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.06.2043 · Cited by 61
Spindler, K. G., Mau‐Sørensen, M., Pallisgaard, N., Andersen, R. F., Havelund, B. M., Pløen, J., Lassen, U., & Jakobsen, A. K. M. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.776175 · Cited by 60
Targeting the mTOR Pathway in Leukemia
Dinner, S. N., & Platanias, L. C. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25559 · Cited by 60
Leiker, A. J., DeGraff, W., Choudhuri, R., Sowers, A. L., Thetford, A., Cook, J. A., Waes, C. V., & Mitchell, J. B. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3279 · Cited by 59
Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer
Deutsch, É., Pechoux, C. L., Faivre, L., Rivera, S., Tao, Y., Pignon, J., Angokai, M., Bahleda, R., Deandreis, D., Angevin, E., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv105 · Cited by 58
Xing, X., Zhang, L., Wen, X., Wang, X., Cheng, X., Du, H., Hu, Y., Li, L., Dong, B., Li, Z., et al. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000148 · Cited by 56
Tang, J. C. O. (2010) · Oncology Reports · doi:10.3892/or_00000832 · Cited by 55
Novel therapies in small cell lung cancer.
Mamdani, H. M., Induru, R. R., & Jalal, S. I. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.07.20 · Cited by 52
Novel Therapies for Small Cell Lung Cancer
Koczywas, M., & Amanam, I. U. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_8 · Cited by 51
The Determinants of Head and Neck Cancer: Unmasking the PI3K Pathway Mutations
Squarize, F. S. G. C. H. (2013) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s5-003 · Cited by 49
Reungwetwattana, T., Molina, J. R., Mandrekar, S. J., Allen-Ziegler, K., Rowland, K. M., Reuter, N. F., Luyun, R. F., Dy, G. K., Marks, R. S., Schild, S. E., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824de0d6 · Cited by 48
Wilson-Edell, K. A., Yevtushenko, M. A., Rothschild, D. E., Rogers, A. N., & Benz, C. C. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-2877-y · Cited by 48
Mellema, W. W., Dingemans, A. C., Thunnissen, E., Snijders, P. J. F., Derks, J. L., Heideman, D. A. M., van Suylen, R. J., & Smit, E. F. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318298764e · Cited by 47
mTOR Complexes as a Nutrient Sensor for Driving Cancer Progression
Harachi, M., Masui, K., Okamura, Y., Tsukui, R., Mischel, P. S., & Shibata, N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103267 · Cited by 47
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
Blaser, B., Waselle, L., Dormond-Meuwly, A., Dufour, M., Roulin, D., Demartines, N., & Dormond, O. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-86 · Cited by 46
Milam, M. R., Celestino, J., Wu, W., Broaddus, R. R., Schmeler, K. M., Slomovitz, B. M., Soliman, P. T., Gershenson, D. M., Wang, H., Ellenson, L. H., et al. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.10.872 · Cited by 45
Amornphimoltham, P., Patel, V., Leelahavanichkul, K., Abraham, R. T., & Gutkind, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1756 · Cited by 45
Fuereder, T., Jaeger-Lansky, A., Hoeflmayer, D., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.04.015 · Cited by 44
Gastric cancer management: Kinases as a target therapy
Farran, B., Müller, S., & Montenegro, R. C. (2017) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12743 · Cited by 44
Wolpin, B. M., Ng, K., Zhu, A. X., Abrams, T. A., Enzinger, P. C., McCleary, N. J., Schrag, D., Kwak, E. L., Allen, J. N., Bhargava, P., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0378 · Cited by 43
Fury, M. G., Sherman, E. J., Ho, A. L., Xiao, H., Tsai, F. Y.-C., Nwankwo, O., Sima, C. S., Heguy, A., Katabi, N., Haque, S. S., et al. (2013) · Cancer · doi:10.1002/cncr.27986 · Cited by 43
Autophagy, p53, and Pancreatic Cancer
Iacobuzio–Donahue, C. A., & Herman, J. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmcibr1400189 · Cited by 41
Chong, M. L., Loh, M. C. S., Thakkar, B. M., Pang, B., Iacopetta, B. J., & Soong, R. (2013) · International Journal of Cancer · doi:10.1002/ijc.28444 · Cited by 40
Ramalingam, S. S., Owonikoko, T. K., Behera, M., Subramanian, J., Saba, N. F., Kono, S. A., Gal, A. A., Sica, G., Harvey, R. D., Chen, Z., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318282709c · Cited by 40
Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer
Cirone, P., Andresen, C. J., Eswaraka, J. R., Lappin, P. B., & Bagi, C. M. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2376-1 · Cited by 39
Role of Phosphatidylinositol-3-Kinase Pathway in Head and Neck Squamous Cell Carcinoma
Du, L., Shen, J., Weems, A. D., & Lu, S. (2012) · Journal of Oncology · doi:10.1155/2012/450179 · Cited by 39
Fury, M. G., Sherman, E. J., Ho, A. L., Katabi, N., Sima, C. S., Kelly, K. W., Nwankwo, O., Haque, S. S., & Pfister, D. G. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1894-y · Cited by 37
Personalized Management of Advanced Kidney Cancer
Graham, J., Heng, D. Y. C., Brugarolas, J., & Vaishampayan, U. N. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_201215 · Cited by 37
Bradshaw‐Pierce, E. L., Pitts, T. M., Kulikowski, G. N., Selby, H. M., Merz, A. L., Gustafson, D. L., Serkova, N. J., Eckhardt, S. G., & Weekes, C. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058089 · Cited by 36
Park, S. J., Lee, T. J., & Chang, I. H. (2011) · Korean journal of urology · doi:10.4111/kju.2011.52.7.466 · Cited by 36
Rogers, S. J., Box, C., Harrington, K. J., Nutting, C. M., Rhys‐Evans, P. H., & Eccles, S. A. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.769 · Cited by 35
Dey, N., Sun, Y., Carlson, J. H., Wu, H., Lin, X., Leyland-Jones, B. R., & De, P. K. (2016) · PubMed · Cited by 34
Seiler, M., Ray-Coquard, I. L., Melichar, B., Yardley, D. A., Wang, R. X., Dodion, P. F., & Lee, M. A. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.07.008 · Cited by 33
Ohara, T., Takaoka, M., Toyooka, S., Tomono, Y., Nishikawa, T., Shirakawa, Y., Yamatsuji, T., Tanaka, N., Fujiwara, T., & Naomoto, Y. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01967.x · Cited by 32
Becker, M. N., Wu, K. J., Marlow, L. A., Kreinest, P. A., Roemeling, C. A. V., Copland, J. A., & WILLIAMS, C. R. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.06.002 · Cited by 31
mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
Gao, W., Li, Z.-H., Chan, J. Y. W., Ho, W., & Wong, T. (2012) · ISRN Otolaryngology · doi:10.5402/2012/953089 · Cited by 30
mTOR inhibitors in urinary bladder cancer
Pinto‐Leite, R., Arantes‐Rodrigues, R., Sousa, N., Oliveira, P. A., & Santos, L. L. (2016) · Tumor Biology · doi:10.1007/s13277-016-5083-1 · Cited by 30
Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?
Tran, P. N., Nguyen, C., & Klempner, S. J. (2016) · International Neurourology Journal · doi:10.5213/inj.1632740.370 · Cited by 30
Gulhati, P., Zaytseva, Y. Y., Valentino, J. D., Stevens, P. D., Kim, J. T., Sasazuki, T., Shirasawa, S., Lee, E. Y., Weiss, H. L., Dong, J., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs203 · Cited by 29
Prognostic implication of TSC1 and mTOR expression in gastric carcinoma
Byeon, S., Han, N., Choi, J., Kim, M. A., & Kim, W. H. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23585 · Cited by 28
Li, L., Liu, D., Qiu, Z.-X., Zhao, S., Zhang, L., & Li, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116771 · Cited by 27
mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC
Coppock, J. D., Vermeer, P. D., Vermeer, D. W., Lee, K. M., Miskimins, W. K., Spanos, W. C., & Lee, J. H. (2016) · Oncotarget · doi:10.18632/oncotarget.8286 · Cited by 22
Chromosomal deletions in bladder cancer: shutting down pathways
Abraham, R. (2006) · Frontiers in bioscience · doi:10.2741/2105 · Cited by 20
The effects of sirolimus on urothelial lesions chemically induced in ICR mice by BBN.
Oliveira, P. A., Arantes‐Rodrigues, R., Sousa-Diniz, C., Colaço, A. A., Lourenço, L., Lf, D. L. C. P., Silva, V. M., Afonso, J., Lopes, C., & Santos, L. L. (2009) · PubMed · Cited by 20
Cho, D. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31829d5cea · Cited by 14
Molecular alterations associated with prostate cancer
García‐Perdomo, H. A., Zapata-Copete, J. A., & Sánchez, A. (2018) · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication · doi:10.5173/ceju.2018.1583 · Cited by 14
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
Gastric cancer: a comprehensive review of current and future treatment strategies
Sexton, R. E., Al Hallak, M. N., Diab, M., & Azmi, A. S. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09925-3 · Cited by 772
PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng, Y., Wang, Y., Zhou, C., Mei, W., & Zeng, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.819128 · Cited by 763
Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104511 · Cited by 591
Metadata
- Authors
- Tian, T., Li, X., & Zhang, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-02-11
- Volume
- 20
- Issue
- 3
- Pages
- 755
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2911580600
- Cited by
- 576
- References
- 286
- FWCI
- 21.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.